The Chronic Kidney Disease Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Diagnosis (Blood Tests, Urine Tests, Imaging Tests, Others), By Treatment (Drug Class, Dialysis, Others), By End-User (Hospital, Diagnostic Laboratories, Others).
In 2024, the market for chronic kidney disease (CKD) continues to address the growing burden of kidney-related morbidity and mortality worldwide, offering comprehensive approaches to prevention, diagnosis, and management of this complex and progressive condition. Chronic kidney disease is characterized by the gradual loss of kidney function over time, leading to complications such as fluid retention, electrolyte imbalances, anemia, and cardiovascular disease. With advancements in understanding CKD pathophysiology, risk stratification, and treatment strategies, the management of CKD aims to slow disease progression, alleviate symptoms, and reduce cardiovascular risk factors for affected individuals. Moreover, the market is influenced by trends such as the integration of multidisciplinary care models and population health management strategies to address CKD risk factors and comorbidities, the development of novel biomarkers and diagnostic tools for early detection and staging of CKD, and the expansion of precision medicine approaches and personalized treatment regimens based on individual patient characteristics and disease trajectory. Additionally, ongoing research focuses on identifying novel therapeutic targets and interventions to halt CKD progression, evaluating the role of lifestyle modifications and dietary interventions in CKD management, and implementing digital health solutions and telemedicine platforms for remote monitoring and management of CKD patients, reflecting the continuous innovation and advancement in CKD care to improve outcomes and quality of life for affected individuals.
A prominent market trend in chronic kidney disease (CKD) is the increasing focus on early detection and prevention strategies. CKD is a progressive condition characterized by the gradual loss of kidney function over time, often leading to end-stage renal disease (ESRD) and the need for dialysis or kidney transplantation. Recognizing the importance of early intervention in slowing disease progression and reducing the risk of complications, healthcare providers and policymakers are placing greater emphasis on screening, diagnosis, and management of CKD in its early stages. This trend towards proactive detection and prevention underscores the importance of public health initiatives, patient education, and integrated care models aimed at identifying individuals at risk for CKD, implementing lifestyle modifications, and optimizing management strategies to preserve kidney function and improve long-term outcomes.
A significant driver fueling the growth of the chronic kidney disease market is the rising incidence of diabetes and hypertension, two leading risk factors for CKD. Diabetes and hypertension are major contributors to the development and progression of CKD, accounting for a significant proportion of cases worldwide. With the global epidemic of obesity, sedentary lifestyles, and unhealthy dietary habits, the prevalence of diabetes and hypertension continues to rise, resulting in an increased burden of CKD and its associated complications. The growing incidence of diabetes and hypertension highlights the urgent need for effective strategies to prevent, detect, and manage CKD in at-risk populations. Healthcare providers, policymakers, and stakeholders are actively working to address the underlying causes of diabetes and hypertension, implement evidence-based guidelines for CKD screening and management, and improve access to comprehensive care services for individuals with or at risk of developing CKD.
An intriguing opportunity within the chronic kidney disease market lies in the development of novel therapies and biomarkers that can effectively slow disease progression, mitigate complications, and improve outcomes for patients with CKD. While current treatment options for CKD focus primarily on managing symptoms, controlling blood pressure, and reducing cardiovascular risk, there remains a significant unmet need for disease-modifying therapies that target the underlying mechanisms of kidney damage and fibrosis. Additionally, there's potential for the discovery and validation of predictive biomarkers that can identify individuals at high risk for CKD progression, guide treatment decisions, and monitor disease activity over time. By investing in research and development efforts aimed at advancing novel therapeutics and biomarkers for CKD, pharmaceutical companies, biotechnology firms, and academic institutions can address critical gaps in CKD management, improve patient outcomes, and contribute to the advancement of kidney health worldwide.
In the Chronic Kidney Disease Market, the segment experiencing rapid growth is Dialysis Treatment for Chronic Kidney Disease in Hospitals. Dialysis is a critical therapy for individuals with end-stage renal disease (ESRD) or advanced stages of chronic kidney disease (CKD) who experience kidney failure and require artificial filtration of blood to remove waste products and excess fluid from the body. With the rising prevalence of CKD globally, particularly in aging populations and those with comorbid conditions such as diabetes and hypertension, there is an increasing demand for dialysis services in hospital settings. Hospitals equipped with comprehensive nephrology departments and advanced dialysis facilities are at the forefront of providing life-sustaining dialysis treatments to CKD patients, offering both inpatient and outpatient dialysis services. Moreover, advancements in dialysis technology, such as hemodialysis and peritoneal dialysis modalities, contribute to the growth of dialysis treatment in hospitals by improving treatment efficacy, safety, and patient comfort. As healthcare systems strive to meet the growing demand for renal replacement therapy and provide comprehensive care for CKD patients, the market for dialysis treatment in hospitals is expected to witness significant growth in the chronic kidney disease market.
The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAbbott Laboratories, AbbVie Inc, Amgen Inc, Bayer AG, Beckman Coulter Inc, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co. Inc, Pfizer Inc, Siemens Healthineers AG, Sysmex Corp, Teva Pharmaceutical Industries Ltd
By Diagnosis
Blood Tests
Urine Tests
Imaging Tests
Others
By Treatment
Drug Class
-ACE Inhibitors
-Angiotensin-II Receptor Blockers
-Diuretics
-Others
Dialysis
Others
By End-User
Hospital
Diagnostic Laboratories
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Abbott Laboratories
AbbVie Inc
Amgen Inc
Bayer AG
Beckman Coulter Inc
Bristol-Myers Squibb Company
F. Hoffmann-La Roche AG
GlaxoSmithKline PLC
Merck & Co. Inc
Pfizer Inc
Siemens Healthineers AG
Sysmex Corp
Teva Pharmaceutical Industries Ltd
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Chronic Kidney Disease Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Chronic Kidney Disease Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Chronic Kidney Disease Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Chronic Kidney Disease Market Size Outlook, $ Million, 2021 to 2030
3.2 Chronic Kidney Disease Market Outlook by Type, $ Million, 2021 to 2030
3.3 Chronic Kidney Disease Market Outlook by Product, $ Million, 2021 to 2030
3.4 Chronic Kidney Disease Market Outlook by Application, $ Million, 2021 to 2030
3.5 Chronic Kidney Disease Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Chronic Kidney Disease Industry
4.2 Key Market Trends in Chronic Kidney Disease Industry
4.3 Potential Opportunities in Chronic Kidney Disease Industry
4.4 Key Challenges in Chronic Kidney Disease Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Chronic Kidney Disease Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Chronic Kidney Disease Market Outlook by Segments
7.1 Chronic Kidney Disease Market Outlook by Segments, $ Million, 2021- 2030
By Diagnosis
Blood Tests
Urine Tests
Imaging Tests
Others
By Treatment
Drug Class
-ACE Inhibitors
-Angiotensin-II Receptor Blockers
-Diuretics
-Others
Dialysis
Others
By End-User
Hospital
Diagnostic Laboratories
Others
8 North America Chronic Kidney Disease Market Analysis and Outlook To 2030
8.1 Introduction to North America Chronic Kidney Disease Markets in 2024
8.2 North America Chronic Kidney Disease Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Chronic Kidney Disease Market size Outlook by Segments, 2021-2030
By Diagnosis
Blood Tests
Urine Tests
Imaging Tests
Others
By Treatment
Drug Class
-ACE Inhibitors
-Angiotensin-II Receptor Blockers
-Diuretics
-Others
Dialysis
Others
By End-User
Hospital
Diagnostic Laboratories
Others
9 Europe Chronic Kidney Disease Market Analysis and Outlook To 2030
9.1 Introduction to Europe Chronic Kidney Disease Markets in 2024
9.2 Europe Chronic Kidney Disease Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Chronic Kidney Disease Market Size Outlook by Segments, 2021-2030
By Diagnosis
Blood Tests
Urine Tests
Imaging Tests
Others
By Treatment
Drug Class
-ACE Inhibitors
-Angiotensin-II Receptor Blockers
-Diuretics
-Others
Dialysis
Others
By End-User
Hospital
Diagnostic Laboratories
Others
10 Asia Pacific Chronic Kidney Disease Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Chronic Kidney Disease Markets in 2024
10.2 Asia Pacific Chronic Kidney Disease Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Chronic Kidney Disease Market size Outlook by Segments, 2021-2030
By Diagnosis
Blood Tests
Urine Tests
Imaging Tests
Others
By Treatment
Drug Class
-ACE Inhibitors
-Angiotensin-II Receptor Blockers
-Diuretics
-Others
Dialysis
Others
By End-User
Hospital
Diagnostic Laboratories
Others
11 South America Chronic Kidney Disease Market Analysis and Outlook To 2030
11.1 Introduction to South America Chronic Kidney Disease Markets in 2024
11.2 South America Chronic Kidney Disease Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Chronic Kidney Disease Market size Outlook by Segments, 2021-2030
By Diagnosis
Blood Tests
Urine Tests
Imaging Tests
Others
By Treatment
Drug Class
-ACE Inhibitors
-Angiotensin-II Receptor Blockers
-Diuretics
-Others
Dialysis
Others
By End-User
Hospital
Diagnostic Laboratories
Others
12 Middle East and Africa Chronic Kidney Disease Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Chronic Kidney Disease Markets in 2024
12.2 Middle East and Africa Chronic Kidney Disease Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Chronic Kidney Disease Market size Outlook by Segments, 2021-2030
By Diagnosis
Blood Tests
Urine Tests
Imaging Tests
Others
By Treatment
Drug Class
-ACE Inhibitors
-Angiotensin-II Receptor Blockers
-Diuretics
-Others
Dialysis
Others
By End-User
Hospital
Diagnostic Laboratories
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott Laboratories
AbbVie Inc
Amgen Inc
Bayer AG
Beckman Coulter Inc
Bristol-Myers Squibb Company
F. Hoffmann-La Roche AG
GlaxoSmithKline PLC
Merck & Co. Inc
Pfizer Inc
Siemens Healthineers AG
Sysmex Corp
Teva Pharmaceutical Industries Ltd
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Diagnosis
Blood Tests
Urine Tests
Imaging Tests
Others
By Treatment
Drug Class
-ACE Inhibitors
-Angiotensin-II Receptor Blockers
-Diuretics
-Others
Dialysis
Others
By End-User
Hospital
Diagnostic Laboratories
Others
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
The global Chronic Kidney Disease Market is one of the lucrative growth markets, poised to register a 6.2% growth (CAGR) between 2024 and 2030.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Abbott Laboratories, AbbVie Inc, Amgen Inc, Bayer AG, Beckman Coulter Inc, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co. Inc, Pfizer Inc, Siemens Healthineers AG, Sysmex Corp, Teva Pharmaceutical Industries Ltd
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume